King Abdulaziz Medical City through CRISPR gene editing technology treats patient with thalassemia major

A 13-year-old kid with thalassaemia major was successfully treated with Casgevy gene therapy employing CRISPR gene editing technology at King Abdulaziz Medical City in Riyadh (KAMC-RD) of the Ministry of National Guard Health Affairs (MNGHA), marking a significant medical advancement for Saudi Arabia. 

With this accomplishment, sophisticated gene therapy will be successfully used for the first time outside of research and clinical trials.

After a successful gene cell transplant, the young patient, who had required blood transfusions every three weeks since birth, has totally recovered and has left the hospital city. 

Saudi Arabia is getting ready to expand the use of these cutting-edge gene treatments to more individuals with sickle cell anaemia and thalassaemia, solidifying its position as a global leader in the area of gene therapy.

 After a successful gene cell transplant, the young patient, who had required blood transfusions every three weeks since birth, has totally recovered and has left the hospital city. 

Saudi Arabia is getting ready to expand the use of these cutting-edge gene treatments to more individuals with sickle cell anaemia and thalassaemia, solidifying its position as a global leader in the area of gene therapy.